2026 Vanna Chiarion-Sileni: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	73	19521	18318	788	754	270	57496

Overview

Vanna Chiarion-Sileni is affiliated with the European Institute of Oncology in Italy. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions to Oncology, Molecular Biology, Immunology, Organic Chemistry, and Pulmonary and Respiratory Medicine.

The scientist's work focuses extensively on topics related to cancer and immunotherapy. These include:

Cancer Immunotherapy and Biomarkers
Melanoma and MAPK Pathways
CAR-T cell therapy research
Cutaneous Melanoma Detection and Management
Immunotherapy and Immune Responses
Click Chemistry and Applications
Brain Metastases and Treatment

Vanna Chiarion-Sileni has published multiple papers in internationally recognized journals. Some of the recent publications are:

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma, 2022, Zurich Open Repository and Archive (University of Zurich)
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial, 2020, The Lancet Oncology
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma, 2020, New England Journal of Medicine
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma, 2024, New England Journal of Medicine

Their frequent collaborators include Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Piotr Rutkowski, and Reinhard Dummer. These collaborations have contributed to an extensive body of work within multiple high-impact venues.

Vanna Chiarion-Sileni has published extensively in several prominent journals, with the most frequent venues being:

Journal of Clinical Oncology
Annals of Oncology
European Journal of Cancer
Frontiers in Oncology
The Lancet Oncology

Best Publications

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

8404
Citations
Nivolumab in previously untreated melanoma without BRAF mutation.

Caroline Robert;Georgina V. Long;Benjamin Brady;Caroline Dutriaux

5803
Citations
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

4954
Citations
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

3875
Citations
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

3410
Citations
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

2792
Citations
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

2152
Citations
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

1464
Citations
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

1423
Citations
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

1395
Citations
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

1316
Citations
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

Frank Stephen Hodi;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

1263
Citations
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance

940
Citations
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

Michael A. Davies;Philippe Saiag;Caroline Robert;Jean Jacques Grob

693
Citations
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

G. V. Long;K. T. Flaherty;D. Stroyakovskiy;H. Gogas

668
Citations
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

S. J. O'Day;M. Maio;V. Chiarion-Sileni;T. F. Gajewski

600
Citations
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

Michele Maio;Jean Jacques Grob;Steinar Aamdal;Igor Bondarenko

543
Citations
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Paolo A. Ascierto;Michele Del Vecchio;Caroline Robert;Andrzej Mackiewicz

533
Citations
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

Dirk Schadendorf;Jedd D. Wolchok;F. Stephen Hodi;Vanna Chiarion-Sileni

490
Citations
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Jean-Jacques Grob

425
Citations

Frequent Co-Authors

Paolo A. Ascierto National Institutes of Health

Caroline Robert University of Paris-Saclay

Dirk Schadendorf University of Duisburg-Essen

Michele Maio University of Siena

Georgina V. Long University of Sydney

Jean-Jacques Grob Aix-Marseille University

Reinhard Dummer University of Zurich

James Larkin Royal Marsden NHS Foundation Trust

Mario Mandalà European Institute of Oncology

Piotr Rutkowski Maria Sklodowska-Curie National Research Institute of Oncology

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

The path to a healthcare career is diverse—students aren’t limited to medical school alone. Many opt for nursing, healthcare administration, or specialized roles like medical billing and coding. If you're seeking alternative routes, consider schools that have a reputation as easy nursing schools to get into. These programs may offer fewer entry barriers, making it possible to launch your career in healthcare sooner.

Not all nursing programs require standardized testing, which broadens access even further. Have questions about entry exams? Investigate institutions on this list: do all nursing schools require the teas. Beyond patient care, those interested in the administrative side can explore healthcare administration accelerated degree options—ideal for career changers or professionals seeking advancement.

For individuals interested in technology and office-based roles, best online medical billing and coding schools provide flexible learning with strong job prospects. Choosing the right pathway depends on your interests, timeline, and educational background.